ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
27 announcements
Mercury Laboratories Ltd reported unaudited financial results for the quarter ended September 30, 2026. The company recorded a net profit of ₹0.67 Crore.
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.
Mercury Laboratories disclosed the cessation of Manager-HR Jaydeepsinh Raj, effective October 28, 2026. The employee stopped reporting for duty without prior intimation to the company.
Mercury Laboratories Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b). The report provides a standard breakdown of the company's current equity ownership structure.
Mr. Dilip Ramanlal Shah has ceased to be a Non-Executive Director of Mercury Laboratories Limited following the non-approval of his re-appointment at the recent AGM.
Mercury Laboratories Limited conducted its 45th Annual General Meeting on September 28, 2026. Shareholders considered agenda items including financial statements adoption and a ₹3.50 per share dividend.
Mercury Laboratories has appointed Mr. Jaydeepsinh Raj as Manager-HR, effective September 03, 2026.
Mercury Laboratories Ltd has submitted its 45th Annual Report and Notice of the 45th AGM for the financial year 2025-26.
Mercury Laboratories has issued the notice for its 45th Annual General Meeting, scheduled for September 28, 2026. The meeting will address dividend declaration and director re-appointments.
Mercury Laboratories appointed Sunil Sharma as Head of Injectable Production effective August 21, 2026. Simultaneously, Ms. Seema Salvi resigned from the same position to pursue other opportunities.
Mercury Laboratories informs shareholders regarding Tax Deduction at Source (TDS) requirements for the FY 2025-26 dividend. This communication outlines necessary compliance and record-updating procedures.
Mercury Laboratories Ltd reported revenue from operations of ₹16 Cr (-11.6% YoY) and net profit of ₹0.3 Cr (-70.0% YoY) for Q1 FY27.
Mercury Laboratories scheduled a board meeting for July 25, 2026. The board will consider and approve unaudited financial results for the June quarter.
CRISIL reaffirmed the credit rating of Mercury Laboratories' ₹3 Crore fixed deposits at 'CRISIL BB+/Stable'. This indicates a moderate risk of default.
Mercury Laboratories Limited appointed Mr. Binaya Kumar Panigrahi as Plant Head for its Jarod Unit. He brings over 24 years of expertise in pharmaceutical tablet manufacturing.
Mercury Laboratories resubmitted its audited FY2026 financial results to correct typographical errors in the balance sheet and cash flow statement. No other material changes were reported.
Mercury Laboratories appointed M/s K R & Associates as Internal Auditor and M/s V. M. Patel & Associates as Cost Auditor for FY 2026-27. Both are re-appointments.
Mercury Laboratories declared a final dividend of ₹3.5 per equity share for FY26. The record date is September 21, 2026, pending shareholder approval at the AGM.
Mercury Laboratories Ltd reported revenue from operations of ₹20.4 Cr (-1.4% YoY) and net profit of ₹1.2 Cr (+9.1% YoY) for Q4 FY26.
Mercury Laboratories approved its FY26 audited results reporting a total income of ₹77.89 Crore. The board recommended a 35% dividend alongside the annual performance update.
Mercury Laboratories filed its Annual Secretarial Compliance Report for the financial year 2025-26. The report by Dholakia & Associates confirms no material non-compliance or penalties.
Mercury Laboratories Limited scheduled a board meeting for May 29, 2026. Directors will consider audited financial results and potential dividend recommendations for the fiscal year.
Mercury Laboratories Ltd has issued an intimation regarding the mandatory transfer of equity shares to the IEPF Authority. This applies to shareholders who have not claimed dividends for seven consecutive years starting from FY 2018-19. Shareholders must claim their unclaimed dividends by November 02, 2026, to avoid the share transfer.
Mercury Laboratories Ltd submitted its annual disclosure for FY 2025-26 under the SEBI Large Corporate framework. The company confirmed it was not identified as a Large Corporate (LC) for the period, resulting in nil mandatory borrowing requirements through debt securities and no applicable penalties.
Mercury Laboratories Limited announced the resignation of Mr. Sandip Patel, Plant Head-Jarod and Senior Management Personnel, effective April 28, 2026. Mr. Patel resigned to pursue better opportunities and career advancement. The company confirmed there are no other material reasons for his departure.
Mercury Laboratories Ltd disclosed an outstanding borrowing of ₹7.31 Crore as of March 31, 2026. Under SEBI's Large Corporate framework, the company confirmed its status and reported a BB+/Stable credit rating from CRISIL Limited.
Mercury Laboratories Ltd submitted its quarterly confirmation certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the period ended March 31, 2026. The registrar, MUFG Intime India, confirmed that security certificates received for dematerialisation were processed and listed on the relevant exchanges within prescribed timelines.